Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C, Haferlach T, Haase D, Fonatsch C, Löffler H, Schlegelberger B, Staib P, Sauerland MC, Heinecke A, Büchner T, Hiddemann W; German AML Cooperative Study Group. Schoch C, et al. Among authors: heinecke a. Br J Haematol. 2001 Jan;112(1):118-26. doi: 10.1046/j.1365-2141.2001.02511.x. Br J Haematol. 2001. PMID: 11167792 Free article. Clinical Trial.
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W. Kern W, et al. Among authors: heinecke a. Blood. 2003 Jan 1;101(1):64-70. doi: 10.1182/blood-2002-02-0532. Epub 2002 Jun 28. Blood. 2003. PMID: 12393605 Free article. Clinical Trial.
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: heinecke a. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. Büchner T, et al. Among authors: heinecke a. J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133. J Clin Oncol. 2003. PMID: 14673036 Clinical Trial.
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
Schoch C, Haase D, Fonatsch C, Haferlach T, Löffler H, Schlegelberger B, Hossfeld DK, Becher R, Sauerland MC, Heinecke A, Wörmann B, Büchner T, Hiddemann W. Schoch C, et al. Among authors: heinecke a. Br J Haematol. 1997 Dec;99(3):605-11. doi: 10.1046/j.1365-2141.1997.4473257.x. Br J Haematol. 1997. PMID: 9401073 Free article.
[The therapy of acute myeloid leukemia in patients of advanced age].
Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: heinecke a. Dtsch Med Wochenschr. 1999 Aug 27;124(34-35):1005-14. doi: 10.1055/s-2007-1024465. Dtsch Med Wochenschr. 1999. PMID: 10488328 Review. German. No abstract available.
Management of acute myeloid leukemia in elderly patients.
Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, Büchner T. Hiddemann W, et al. Among authors: heinecke a. J Clin Oncol. 1999 Nov;17(11):3569-76. doi: 10.1200/JCO.1999.17.11.3569. J Clin Oncol. 1999. PMID: 10550156 Review.
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
Büchner T, Hiddemann W, Wörmann B, Löffler H, Ludwig WD, Schoch C, Haferlach T, Maschmeyer G, Staib P, Aul C, Heyll GA, Grüneisen A, Rasche H, Eimermacher JH, Balleisen L, Pielken HJ, Reis HE, Griesinger F, Reichle A, Sauerland MC, Heinecke A; German AMLCG. Büchner T, et al. Among authors: heinecke a. Int J Hematol. 2000 Oct;72(3):285-9. Int J Hematol. 2000. PMID: 11185983
244 results